Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy
Alemtuzumab is a pan-lymphocyte depleting anti-CD52 antibody, and is approved as an escalation therapy for patients with multiple sclerosis with active disease defined by clinical or imaging features. In phase 3 clinical trials, the drug was more effective than interferon beta-1a in reducing relapse...
Full description
Bibliographic Details
| Main Authors: |
Haghikia, A,
Dendrou, C,
Schneider, R,
Grüter, T,
Postert, T,
Matzke, M,
Stephanik, H,
Fugger, L,
Gold, R |
|---|
| Format: | Journal article
|
|---|
| Language: | English |
|---|
| Published: |
Lancet
2017
|
|---|